These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 23756858)

  • 1. Intratumoral concentration of estrogens and clinicopathological changes in ductal carcinoma in situ following aromatase inhibitor letrozole treatment.
    Takagi K; Ishida T; Miki Y; Hirakawa H; Kakugawa Y; Amano G; Ebata A; Mori N; Nakamura Y; Watanabe M; Amari M; Ohuchi N; Sasano H; Suzuki T
    Br J Cancer; 2013 Jul; 109(1):100-8. PubMed ID: 23756858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DCIS and aromatase inhibitors.
    Dixon JM; Faratian D; White S; Renshaw L; Murray J; Young O; Macaskill EJ; Williams L; Thomas J; Evans DB
    J Steroid Biochem Mol Biol; 2007; 106(1-5):173-9. PubMed ID: 17604618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumor effects of letrozole.
    Miller WR; Anderson TJ; Dixon JM
    Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance).
    Hwang ES; Hyslop T; Hendrix LH; Duong S; Bedrosian I; Price E; Caudle A; Hieken T; Guenther J; Hudis CA; Winer E; Lyss AP; Dickson-Witmer D; Hoefer R; Ollila DW; Hardman T; Marks J; Chen YY; Krings G; Esserman L; Hylton N
    J Clin Oncol; 2020 Apr; 38(12):1284-1292. PubMed ID: 32125937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole.
    Miller WR; Larionov A
    Breast Cancer Res; 2010; 12(4):R52. PubMed ID: 20646288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.
    Lykkesfeldt AE; Henriksen KL; Rasmussen BB; Sasano H; Evans DB; Møller S; Ejlertsen B; Mouridsen HT
    BMC Cancer; 2009 Jun; 9():185. PubMed ID: 19531212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postmenopausal women with DCIS post-mastectomy: a potential role for aromatase inhibitors.
    Chlebowski RT; Col N
    Breast J; 2012; 18(4):299-302. PubMed ID: 22681627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women.
    Murray J; Young OE; Renshaw L; White S; Williams L; Evans DB; Thomas JS; Dowsett M; Dixon JM
    Breast Cancer Res Treat; 2009 Apr; 114(3):495-501. PubMed ID: 18438705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea.
    Beom SH; Oh J; Kim TY; Lee KH; Yang Y; Suh KJ; Moon HG; Han SW; Oh DY; Han W; Kim TY; Noh DY; Im SA
    Cancer Res Treat; 2017 Apr; 49(2):454-463. PubMed ID: 27554482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superior suppression of serum estrogens during neoadjuvant breast cancer treatment with letrozole compared to exemestane.
    Bertelsen BE; Almås B; Fjermeros K; Viste K; Geisler SB; Sauer T; Selsås K; Geisler J
    Breast Cancer Res Treat; 2024 Jul; 206(2):347-358. PubMed ID: 38649619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
    Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
    Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors.
    Lønning PE; Haynes BP; Dowsett M
    Eur J Cancer; 2014 Apr; 50(6):1055-64. PubMed ID: 24507547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biology of aromatase inhibitors: pharmacology/endocrinology within the breast.
    Miller WR
    Endocr Relat Cancer; 1999 Jun; 6(2):187-95. PubMed ID: 10731108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes.
    Dixon JM; Jackson J; Renshaw L; Miller WR
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):295-9. PubMed ID: 14623524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
    Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
    Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of aromatase inhibitors in the management of ductal carcinoma in situ with an estrogen receptor-positive/progesterone receptor-negative/Her-2/neu receptor-positive pattern.
    Altundag K; Bulut N; Sari E; Harputluoglu H
    Am J Surg; 2007 Aug; 194(2):272-3. PubMed ID: 17618822
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer.
    Llombart-Cussac A; Guerrero Á; Galán A; Carañana V; Buch E; Rodríguez-Lescure Á; Ruiz A; Fuster Diana C; Guillem Porta V
    Clin Transl Oncol; 2012 Feb; 14(2):125-31. PubMed ID: 22301401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
    Long BJ; Jelovac D; Thiantanawat A; Brodie AM
    Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local endocrine effects of aromatase inhibitors within the breast.
    Miller WR; Dixon JM
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):93-102. PubMed ID: 11850212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer.
    Arnedos M; Drury S; Afentakis M; A'Hern R; Hills M; Salter J; Smith IE; Reis-Filho JS; Dowsett M
    Ann Oncol; 2014 Mar; 25(3):605-610. PubMed ID: 24525703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.